Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems

Krisztina Kiss, Beáta Biri-Kovács, Rita Szabó, Ivan Ranđelović, Kata Nóra Enyedi, G. Schlosser, Ádám Orosz, Bence Kapuvári, J. Tóvári, G. Mező

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Development of peptide-based conjugates for targeted tumour therapy is a current research topic providing new possibilities in cancer treatment. In this study, VHLGYAT heptapeptide selected by phage display technique for HT-29 human colon cancer was investigated as homing peptide for drug delivery. Daunomycin was conjugated to the N-terminus of the peptide directly or through Cathepsin B cleavable spacers. Conjugates showed moderate in vitro cytostatic effect. Therefore, sequence modifications were performed by Ala-scan and positional scanning resulting in conjugates with much higher bioactivity. Conjugates in which Gly was replaced by amino acids with bulky apolaric side chains provided the best efficacy. The influence of the cellular uptake, stability and drug release on the anti-tumour activity was investigated. It was found that mainly the difference in the cellular uptake of the conjugates generated the distinct effect on cell viability. One of the most efficient conjugate Dau = Aoa-LRRY-VHLFYAT-NH 2 showed tumour growth inhibition on orthotopically developed HT-29 colon cancer in mice with negligible toxic side effect compared to the free drug. We also indicate that this sequence is not specific to HT-29 cells, but it has a remarkable effect on many other cancer cells. Nevertheless, the Phe-containing conjugate was more active in all cases compared to the conjugate with the parent sequence. The literature data suggested that this sequence is highly overlapped with peptides that recognize Hsp70 membrane bound protein overexpressed in many types of tumours.

Original languageEnglish
Pages (from-to)105-116
Number of pages12
JournalEuropean Journal of Medicinal Chemistry
Volume176
DOIs
Publication statusPublished - Aug 15 2019

Fingerprint

Bacteriophages
Drug Delivery Systems
Colonic Neoplasms
Tumors
Display devices
Cells
Equipment and Supplies
Peptides
Neoplasms
Cathepsin B
Daunorubicin
Oncology
Poisons
Cell Surface Display Techniques
Cytostatic Agents
Bioactivity
Drug delivery
Pharmaceutical Preparations
HT29 Cells
Membranes

Keywords

  • Daunomycin
  • Drug delivery system
  • Drug release
  • Phage display
  • Small molecule drug conjugate
  • Targeted cancer therapy

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems. / Kiss, Krisztina; Biri-Kovács, Beáta; Szabó, Rita; Ranđelović, Ivan; Enyedi, Kata Nóra; Schlosser, G.; Orosz, Ádám; Kapuvári, Bence; Tóvári, J.; Mező, G.

In: European Journal of Medicinal Chemistry, Vol. 176, 15.08.2019, p. 105-116.

Research output: Contribution to journalArticle

Kiss, Krisztina ; Biri-Kovács, Beáta ; Szabó, Rita ; Ranđelović, Ivan ; Enyedi, Kata Nóra ; Schlosser, G. ; Orosz, Ádám ; Kapuvári, Bence ; Tóvári, J. ; Mező, G. / Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems. In: European Journal of Medicinal Chemistry. 2019 ; Vol. 176. pp. 105-116.
@article{c2fa0bd793d445609427955b077dc1ef,
title = "Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems",
abstract = "Development of peptide-based conjugates for targeted tumour therapy is a current research topic providing new possibilities in cancer treatment. In this study, VHLGYAT heptapeptide selected by phage display technique for HT-29 human colon cancer was investigated as homing peptide for drug delivery. Daunomycin was conjugated to the N-terminus of the peptide directly or through Cathepsin B cleavable spacers. Conjugates showed moderate in vitro cytostatic effect. Therefore, sequence modifications were performed by Ala-scan and positional scanning resulting in conjugates with much higher bioactivity. Conjugates in which Gly was replaced by amino acids with bulky apolaric side chains provided the best efficacy. The influence of the cellular uptake, stability and drug release on the anti-tumour activity was investigated. It was found that mainly the difference in the cellular uptake of the conjugates generated the distinct effect on cell viability. One of the most efficient conjugate Dau = Aoa-LRRY-VHLFYAT-NH 2 showed tumour growth inhibition on orthotopically developed HT-29 colon cancer in mice with negligible toxic side effect compared to the free drug. We also indicate that this sequence is not specific to HT-29 cells, but it has a remarkable effect on many other cancer cells. Nevertheless, the Phe-containing conjugate was more active in all cases compared to the conjugate with the parent sequence. The literature data suggested that this sequence is highly overlapped with peptides that recognize Hsp70 membrane bound protein overexpressed in many types of tumours.",
keywords = "Daunomycin, Drug delivery system, Drug release, Phage display, Small molecule drug conjugate, Targeted cancer therapy",
author = "Krisztina Kiss and Be{\'a}ta Biri-Kov{\'a}cs and Rita Szab{\'o} and Ivan Ranđelović and Enyedi, {Kata N{\'o}ra} and G. Schlosser and {\'A}d{\'a}m Orosz and Bence Kapuv{\'a}ri and J. T{\'o}v{\'a}ri and G. Mező",
year = "2019",
month = "8",
day = "15",
doi = "10.1016/j.ejmech.2019.05.016",
language = "English",
volume = "176",
pages = "105--116",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems

AU - Kiss, Krisztina

AU - Biri-Kovács, Beáta

AU - Szabó, Rita

AU - Ranđelović, Ivan

AU - Enyedi, Kata Nóra

AU - Schlosser, G.

AU - Orosz, Ádám

AU - Kapuvári, Bence

AU - Tóvári, J.

AU - Mező, G.

PY - 2019/8/15

Y1 - 2019/8/15

N2 - Development of peptide-based conjugates for targeted tumour therapy is a current research topic providing new possibilities in cancer treatment. In this study, VHLGYAT heptapeptide selected by phage display technique for HT-29 human colon cancer was investigated as homing peptide for drug delivery. Daunomycin was conjugated to the N-terminus of the peptide directly or through Cathepsin B cleavable spacers. Conjugates showed moderate in vitro cytostatic effect. Therefore, sequence modifications were performed by Ala-scan and positional scanning resulting in conjugates with much higher bioactivity. Conjugates in which Gly was replaced by amino acids with bulky apolaric side chains provided the best efficacy. The influence of the cellular uptake, stability and drug release on the anti-tumour activity was investigated. It was found that mainly the difference in the cellular uptake of the conjugates generated the distinct effect on cell viability. One of the most efficient conjugate Dau = Aoa-LRRY-VHLFYAT-NH 2 showed tumour growth inhibition on orthotopically developed HT-29 colon cancer in mice with negligible toxic side effect compared to the free drug. We also indicate that this sequence is not specific to HT-29 cells, but it has a remarkable effect on many other cancer cells. Nevertheless, the Phe-containing conjugate was more active in all cases compared to the conjugate with the parent sequence. The literature data suggested that this sequence is highly overlapped with peptides that recognize Hsp70 membrane bound protein overexpressed in many types of tumours.

AB - Development of peptide-based conjugates for targeted tumour therapy is a current research topic providing new possibilities in cancer treatment. In this study, VHLGYAT heptapeptide selected by phage display technique for HT-29 human colon cancer was investigated as homing peptide for drug delivery. Daunomycin was conjugated to the N-terminus of the peptide directly or through Cathepsin B cleavable spacers. Conjugates showed moderate in vitro cytostatic effect. Therefore, sequence modifications were performed by Ala-scan and positional scanning resulting in conjugates with much higher bioactivity. Conjugates in which Gly was replaced by amino acids with bulky apolaric side chains provided the best efficacy. The influence of the cellular uptake, stability and drug release on the anti-tumour activity was investigated. It was found that mainly the difference in the cellular uptake of the conjugates generated the distinct effect on cell viability. One of the most efficient conjugate Dau = Aoa-LRRY-VHLFYAT-NH 2 showed tumour growth inhibition on orthotopically developed HT-29 colon cancer in mice with negligible toxic side effect compared to the free drug. We also indicate that this sequence is not specific to HT-29 cells, but it has a remarkable effect on many other cancer cells. Nevertheless, the Phe-containing conjugate was more active in all cases compared to the conjugate with the parent sequence. The literature data suggested that this sequence is highly overlapped with peptides that recognize Hsp70 membrane bound protein overexpressed in many types of tumours.

KW - Daunomycin

KW - Drug delivery system

KW - Drug release

KW - Phage display

KW - Small molecule drug conjugate

KW - Targeted cancer therapy

UR - http://www.scopus.com/inward/record.url?scp=85065550701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065550701&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2019.05.016

DO - 10.1016/j.ejmech.2019.05.016

M3 - Article

AN - SCOPUS:85065550701

VL - 176

SP - 105

EP - 116

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -